TRACON Pharmaceuticals Statistics
Total Valuation
TRACON Pharmaceuticals has a market cap or net worth of 380,284. The enterprise value is -4.99 million.
| Market Cap | 380,284 |
| Enterprise Value | -4.99M |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TRACON Pharmaceuticals has 3.41 million shares outstanding. The number of shares has increased by 80.20% in one year.
| Shares Outstanding | 3.41M |
| Shares Change (YoY) | +80.20% |
| Shares Change (QoQ) | +25.89% |
| Owned by Insiders (%) | 1.72% |
| Owned by Institutions (%) | 4.86% |
| Float | 3.35M |
Valuation Ratios
The trailing PE ratio is 0.05.
| PE Ratio | 0.05 |
| Forward PE | n/a |
| PS Ratio | 0.08 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.96 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.66
| Current Ratio | 0.66 |
| Quick Ratio | 0.63 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.28 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -59.37% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 188,235 |
| Profits Per Employee | 305,588 |
| Employee Count | 17 |
| Asset Turnover | 0.33 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -97.43% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -97.43% |
| 50-Day Moving Average | 0.21 |
| 200-Day Moving Average | 2.45 |
| Relative Strength Index (RSI) | 44.10 |
| Average Volume (20 Days) | 31,451 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.09 |
Income Statement
In the last 12 months, TRACON Pharmaceuticals had revenue of 3.20 million and earned 5.20 million in profits. Earnings per share was 2.27.
| Revenue | 3.20M |
| Gross Profit | -8.91M |
| Operating Income | -9.31M |
| Pretax Income | 5.20M |
| Net Income | 5.20M |
| EBITDA | -9.29M |
| EBIT | -9.31M |
| Earnings Per Share (EPS) | 2.27 |
Balance Sheet
The company has 6.27 million in cash and 898,000 in debt, giving a net cash position of 5.37 million or 1.58 per share.
| Cash & Cash Equivalents | 6.27M |
| Total Debt | 898,000 |
| Net Cash | 5.37M |
| Net Cash Per Share | 1.58 |
| Equity (Book Value) | -3.09M |
| Book Value Per Share | -0.91 |
| Working Capital | -3.38M |
Cash Flow
| Operating Cash Flow | 9.22M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is -278.31%, with operating and profit margins of -290.78% and 162.34%.
| Gross Margin | -278.31% |
| Operating Margin | -290.78% |
| Pretax Margin | 162.34% |
| Profit Margin | 162.34% |
| EBITDA Margin | -290.34% |
| EBIT Margin | -290.78% |
| FCF Margin | n/a |
Dividends & Yields
TRACON Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -80.20% |
| Shareholder Yield | -80.20% |
| Earnings Yield | 2,038.41% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on April 10, 2024. It was a reverse split with a ratio of 0.05.
| Last Split Date | Apr 10, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
TRACON Pharmaceuticals has an Altman Z-Score of -50.52. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -50.52 |
| Piotroski F-Score | n/a |